Laser treatment for basal cell carcinoma using advanced imaging
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
This study is testing if using special imaging to guide laser treatment can help people with basal cell carcinoma get better results with fewer side effects.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of California, Irvine Academic / other |
| Locations | 1 site (Irvine, California) |
| Trial ID | NCT04744935 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates the use of optical coherence tomography (OCT) to guide laser treatment for basal cell carcinoma (BCC). The treatment employs a long-pulse Nd:YAG 1064nm laser, which is a non-ablative laser known for its effectiveness against BCC. By utilizing OCT imaging, the study aims to enhance treatment precision and monitoring, potentially improving patient outcomes while minimizing side effects. The study focuses on patients with BCC who are scheduled for treatment and have previously confirmed diagnoses.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have a biopsy-confirmed diagnosis of basal cell carcinoma and are seeking treatment.
Not a fit: Patients with large lesions requiring excision, periocular BCCs, or those with poor wound healing may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer treatment options for patients with basal cell carcinoma.
How similar studies have performed: While laser treatment for BCC has limited precedent, the integration of OCT for guidance is a novel approach that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to understand and carry out subject instructions or be represented by a legally authorized guardian or representative * Ages 18 and older * Seeks and is scheduled for treatment of a BCC previously confirmed with biopsy Exclusion Criteria: Any of the following will exclude participation in the study: * Inability to understand and/or carry out instructions * Patients with a BCC lesion that requires excision. This would include relatively large lesions (\>2.5 cm diameter), lesions that penetrate deep into the skin beyond the depth of the OCT image capture, high risk lesions as defined by the American Academy of Dermatology as recurrent and sclerosing subtype BCC, or metastases. * Patients with periocular BCCs which might expose the patient to risk of damage to eyes from the laser. * BCCs on legs due to their tendency towards poor wound healing. * Pregnancy * Patients unable to follow-up for the full 12 months.
Where this trial is running
Irvine, California
- UCI Health Gottschalk Medical Plaza — Irvine, California, United States (Recruiting)
Study contacts
- Principal investigator: Christopher Zachary, MBBS FRCP — University of California, Irvine
- Study coordinator: Feben Messele
- Email: fmessele@hs.uci.edu
- Phone: 949-824-5515
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.